Functional Genomic Analysis of Drug Sensitivity Pathways to Guide Adjuvant Strategies in Breast Cancer

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2008 Nov 7

PMID 18986507

Citations 10

Authors

Charles Swanton

Zoltan Szallasi

James D Brenton

Julian Downward

Affiliations

Soon will be listed here.

Abstract

The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen. Given the limited power of microarray signatures to predict therapeutic response in associative studies of small clinical trial cohorts, the use of functional genomic data combined with expression or sequence analysis of genes and microRNAs implicated in drug response in human tumours may provide a more robust method to guide adjuvant treatment strategies in breast cancer that are transferable across different expression platforms and patient cohorts.

Citing Articles

Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance.

Alyateem G, Wade H, Bickert A, Lipsey C, Mondal P, Smith M Cancer Gene Ther. 2023; 30(8):1043-1050.

PMID: 37029320 PMC: 10722205. DOI: 10.1038/s41417-023-00608-z.

Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.

Lai T, Fang C, Jan Y, Hsieh H, Yang Y, Liu C Cell Commun Signal. 2020; 18(1):164.

PMID: 33087151 PMC: 7579951. DOI: 10.1186/s12964-020-00600-2.

New tools for old drugs: Functional genetic screens to optimize current chemotherapy.

Gerhards N, Rottenberg S Drug Resist Updat. 2018; 36:30-46.

PMID: 29499836 PMC: 5844649. DOI: 10.1016/j.drup.2018.01.001.

Prediction of individual response to anticancer therapy: historical and future perspectives.

Unger F, Witte I, David K Cell Mol Life Sci. 2014; 72(4):729-57.

PMID: 25387856 PMC: 4309902. DOI: 10.1007/s00018-014-1772-3.

Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Truman J, Garcia-Barros M, Obeid L, Hannun Y Biochim Biophys Acta. 2014; 1841(8):1174-88.

PMID: 24384461 PMC: 4221100. DOI: 10.1016/j.bbalip.2013.12.013.

References

Blower P, Chung J, Verducci J, Lin S, Park J, Dai Z . MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008; 7(1):1-9. DOI: 10.1158/1535-7163.MCT-07-0573. View

Carter S, Eklund A, Kohane I, Harris L, Szallasi Z . A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006; 38(9):1043-8. DOI: 10.1038/ng1861. View

Schetter A, Leung S, Sohn J, Zanetti K, Bowman E, Yanaihara N . MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4):425-36. PMC: 2614237. DOI: 10.1001/jama.299.4.425. View

Ein-Dor L, Kela I, Getz G, Givol D, Domany E . Outcome signature genes in breast cancer: is there a unique set?. Bioinformatics. 2004; 21(2):171-8. DOI: 10.1093/bioinformatics/bth469. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93(4):387-91. PMC: 2361579. DOI: 10.1038/sj.bjc.6602678. View

J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

Ein-Dor L, Zuk O, Domany E . Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A. 2006; 103(15):5923-8. PMC: 1458674. DOI: 10.1073/pnas.0601231103. View

Naderi A, Teschendorff A, Barbosa-Morais N, Pinder S, Green A, Powe D . A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2006; 26(10):1507-16. DOI: 10.1038/sj.onc.1209920. View

Swanton C, Marani M, Pardo O, Warne P, Kelly G, Sahai E . Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell. 2007; 11(6):498-512. DOI: 10.1016/j.ccr.2007.04.011. View

10.

Lee J, Havaleshko D, Cho H, Weinstein J, Kaldjian E, Karpovich J . A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007; 104(32):13086-91. PMC: 1941805. DOI: 10.1073/pnas.0610292104. View

11.

Ahmed A, Mills A, Ibrahim A, Temple J, Blenkiron C, Vias M . The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007; 12(6):514-27. PMC: 2148463. DOI: 10.1016/j.ccr.2007.11.014. View

12.

Ahmed A, Brenton J . Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt. Breast Cancer Res. 2005; 7(3):96-9. PMC: 1143564. DOI: 10.1186/bcr1017. View

13.

Natowicz R, Incitti R, Horta E, Charles B, Guinot P, Yan K . Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses. BMC Bioinformatics. 2008; 9:149. PMC: 2292140. DOI: 10.1186/1471-2105-9-149. View

14.

Bartz S, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A . Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol. 2006; 26(24):9377-86. PMC: 1698535. DOI: 10.1128/MCB.01229-06. View

15.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

16.

Michiels S, Koscielny S, Hill C . Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005; 365(9458):488-92. DOI: 10.1016/S0140-6736(05)17866-0. View

17.

Eden P, Ritz C, Rose C, Ferno M, Peterson C . "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer. 2004; 40(12):1837-41. DOI: 10.1016/j.ejca.2004.02.025. View

18.

Swanton C, Nicke B, Marani M, Kelly G, Downward J . Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs. Cell Cycle. 2007; 6(16):2001-4. DOI: 10.4161/cc.6.16.4538. View

19.

Saal L, Holm K, Maurer M, Memeo L, Su T, Wang X . PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005; 65(7):2554-9. DOI: 10.1158/0008-5472-CAN-04-3913. View

20.

Hess K, Anderson K, Fraser Symmans W, Valero V, Ibrahim N, Mejia J . Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006; 24(26):4236-44. DOI: 10.1200/JCO.2006.05.6861. View